HIV Seronegativity Clinical Trial
Official title:
CCTG 603: Randomized Controlled Trial of iTAB Plus Motivational Interviewing for PrEP Adherence in Transgender Individuals (The iM-PrEPT Study)
CCTG 603 is an open-label, two-arm, randomized (1:1) clinical demonstration project to determine if brief Motivational Interviewing (MI-B) added to a text-message based adherence intervention (iTAB) improves adherence to PrEP among transgender persons.
A total of 300 HIV-uninfected transgender or gender non-conforming individuals, defined as currently identifying as a gender different from sex assigned at birth, with high-risk transmission behavior will be enrolled into this study. Each participant will be followed for a maximum of 48 weeks after enrollment. The primary endpoint will be measured at 48 weeks, or the last week on study if the participant is discontinued early. All participants will start PrEP with TDF / FTC fixed dose combination taken once daily. Subjects will be randomized (1:1) to the iTAB text messaging adherence reminder intervention either with or without brief motivational interviewing (MI-b) for suboptimal adherence. All participants will receive the iTAB system to provide personalized, automated text messages to support and monitor adherence. In the MI-b arm, poor adheres by iTAB reporting will receive targeted MI-b via telephone. Both groups will receive PrEP in accordance with standardized comprehensive methods of prescribing, which includes risk reduction counseling, adherence counseling, and clinical assessments with safety monitoring, as well as HIV and STI screening. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT00065741 -
Botanical/Drug Interactions in HIV: Glucuronidation
|
Phase 1 | |
| Completed |
NCT00056953 -
Peer Mentors for Adolescents in HIV Affected Families
|
Phase 2 | |
| Completed |
NCT00047931 -
HIV-1 Vaccine Test in Uninfected Adult Volunteers
|
Phase 1 | |
| Completed |
NCT03995862 -
Evaluation of Pre-Exposure Prophylaxis Against HIV in Alpine Region
|
||
| Completed |
NCT00006327 -
Effectiveness of AIDSVAX B/E Vaccine in Intravenous Drug Users in Bangkok, Thailand
|
Phase 3 | |
| Completed |
NCT00076817 -
Safety and Effectiveness of Administering an HIV Vaccine in the Groin Versus the Arm
|
Phase 1 | |
| Completed |
NCT03191474 -
Linkage of Transgender Individuals to PrEP
|
N/A | |
| Completed |
NCT00121121 -
Safety of Intradermal Versus Intramuscular Administration of HIV Lipopeptides in HIV Uninfected Adult Volunteers
|
Phase 1 | |
| Completed |
NCT00009685 -
HIV-1 Vaccine Test in Uninfected Adult Volunteers
|
Phase 1 | |
| Completed |
NCT00031304 -
Screening Protocol for HIV Vaccine Studies
|
||
| Completed |
NCT00055237 -
Bevacizumab to Treat Kaposi's Sarcoma in HIV-Positive and HIV-Negative Patients
|
Phase 2 | |
| Completed |
NCT02125773 -
Pre-exposure Prophylaxis Accessibility Research and Evaluation 2
|
N/A | |
| Terminated |
NCT00789789 -
Cohort Study of Volunteers That Have Participated to Preventive HIV-1 Vaccine Trials
|
N/A | |
| Completed |
NCT01761643 -
CCTG 595: Text Messaging Intervention to Improve Adherence to PrEP in High-risk MSM
|
Phase 4 | |
| Completed |
NCT01418235 -
Safety of and Immune Response to a DNA HIV Vaccine Boosted With a Modified Vaccinia HIV Vaccine and Protein HIV Vaccine in Healthy Adults
|
Phase 1 | |
| Completed |
NCT00028119 -
HIV Incidence and Participation Retention in Pune, India
|
||
| Completed |
NCT00076232 -
A Study of Acyclovir to Help Prevent HIV Infection in People With Genital Herpes
|
Phase 3 | |
| Completed |
NCT00004579 -
A Study to See Whether Two HIV Vaccines Are Safe and Can Prevent HIV Infection
|
Phase 1 | |
| Active, not recruiting |
NCT00013572 -
HIV Candidate Vaccine, ALVAC-HIV-1, Administration in HIV-Negative Adults
|
Phase 1 | |
| Completed |
NCT00002441 -
Effectiveness of an HIV Vaccine in HIV-Negative Adults in North America Who Are at Risk of HIV Infection
|
Phase 3 |